Inhibrx Biosciences President Sees 50,000‑Share Options Amid Mixed Insider Sales and Upcoming Director Elections—Market Watches for Confidence Shift

Insider Activity at Inhibrx Biosciences: A Snapshot of Confidence and Caution

Matly David, the president of Inhibrx Biosciences, has exercised a 50,000‑share stock option on April 24, 2026, effectively locking in a sizeable position in a company whose shares recently surged more than 59 % in the week and nearly 1,022 % year‑to‑date. The option, priced at zero, will vest over 36 months, suggesting that David is betting on a long‑term upside while also committing to continuous service. Such a move can be read as a signal of executive conviction, especially in a biotech firm that has already undergone a spin‑off and a product‑line sale.

The broader insider landscape paints a picture of both liquidity and commitment. Viking Global Investors has sold large blocks of common stock in October 2025, reducing its holdings dramatically. Meanwhile, a cohort of junior insiders—Kristiina Vuori, Jon Faiz, Douglas Forsyth, and Kimberly Manhard—have all purchased 15,000‑share options on May 28, 2025, indicating that newer executives see growth potential. The most recent insider sale by Jon Faiz in March 2025, where he liquidated 90,000 shares, underscores that insiders are not averse to taking profits when the market rallies.

For investors, these actions translate into a mixed signal. On one hand, the president’s commitment to a long‑term option vesting schedule aligns with a stewardship model that could drive disciplined capital allocation and strategic focus. On the other hand, the significant secondary sales by institutional holders raise questions about liquidity and confidence in the company’s near‑term prospects. The market’s recent bullish run—peaking at a 52‑week high of $155.29 and a current price of $129.06—offers a cushion, but the negative P/E ratio and the steep decline in share price over the past year warn of potential volatility.

Looking ahead, the upcoming virtual shareholders’ meeting in June, where two Class II directors will be elected and an audit firm ratified, could provide a formal endorsement of the company’s governance trajectory. If the new directors signal a preference for incremental growth and prudent risk management, the market may reward the company with a more stable valuation. Conversely, if investors perceive the insider activity as a lack of confidence, the stock could face renewed pressure. In the biotech space, where regulatory approvals and product pipelines are decisive, the combination of insider confidence, governance updates, and market sentiment will be critical in shaping Inhibrx’s next chapter.